Cargando…

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity. To address this problem, a novel trivalent PEGylated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Shiwen, Sun, Dong, Wang, Hong, Wang, Jinliang, Yan, Huijing, Zhao, Xuan, Fawcett, John Paul, Xu, Xin, Cai, Deqi, Gu, Jingkai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466002/ https://www.ncbi.nlm.nih.gov/pubmed/37655324 http://dx.doi.org/10.1016/j.apsb.2023.01.011

Ejemplares similares

Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug
por: DONG, Xinrui, et al.
Publicado: (2017)

PEGylated Doxorubicin Prodrug-Forming Reduction-Sensitive Micelles With High Drug Loading and Improved Anticancer Therapy
por: Wang, Dongdong, et al.
Publicado: (2021)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes
por: Zhai, Bingtao, et al.
Publicado: (2020)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
por: Gautam, Nagsen, et al.
Publicado: (2021)

Schiff-Linked PEGylated Doxorubicin Prodrug Forming pH-Responsive Nanoparticles With High Drug Loading and Effective Anticancer Therapy
por: Song, Jian, et al.
Publicado: (2021)

Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity
por: Dong, Dong, et al.
Publicado: (2019)

Understanding the pharmacokinetics of prodrug and metabolite
por: Cho, Seungil, et al.
Publicado: (2018)

Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug
por: Wang, Jing-Hung, et al.
Publicado: (2016)

A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug
por: Kulkarni, Tanmay A., et al.
Publicado: (2020)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Structure-based design of anticancer prodrug PABA/NO
por: Ji, Xinhua, et al.
Publicado: (2009)

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report
por: Amzerin, Mounia, et al.
Publicado: (2015)

Stealth Liposomes (PEGylated) Containing an Anticancer Drug Camptothecin: In Vitro Characterization and In Vivo Pharmacokinetic and Tissue Distribution Study
por: Sivadasan, Durgaramani, et al.
Publicado: (2022)

Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome
por: Zhang, Huiyun, et al.
Publicado: (2022)

The Alleviation of LPS-Induced Murine Acute Lung Injury by GSH-Mediated PEGylated Artesunate Prodrugs
por: Hao, Dan-Li, et al.
Publicado: (2022)

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats
por: Cao, Xiaohan, et al.
Publicado: (2014)

Synthesis of a novel PEGylated colon-specific azo-based 4- aminosalicylic acid prodrug
por: Sadeghi, Fatemeh, et al.
Publicado: (2020)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity
por: Pei, Xibo, et al.
Publicado: (2020)

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro—In Vivo Correlation
por: Dubaj, Tibor, et al.
Publicado: (2022)

Pharmacokinetics, Biodistribution, and Biosafety of PEGylated Gold Nanoparticles In Vivo
por: Kozics, Katarina, et al.
Publicado: (2021)

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
por: Sherstoboev, E. Yu., et al.
Publicado: (2022)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
por: Fan, Yingfang, et al.
Publicado: (2017)

Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body
por: Idili, Andrea, et al.
Publicado: (2019)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy
por: El-Sayed, Ashraf S.A., et al.
Publicado: (2022)

Comparative studies on the interaction of anticancer drug irinotecan with dsDNA and ssDNA
por: Temerk, Yassien, et al.
Publicado: (2018)

Synthesis, Biological Evaluation, and Pharmacokinetic Study of Novel Liguzinediol Prodrugs
por: Liu, Zheng, et al.
Publicado: (2013)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Combinatorial Effects of Thymoquinone on the Anticancer Activity and Hepatotoxicity of the Prodrug CB 1954
por: Talib, Wamidh H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dovblovco6b1aj6eq1b2uems38